Cheong-Il Shin

Cheong-Il Shin

Auto-generated profile, based on publicly available information

Cheong-Il Shin

Seoul National University Hospital

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Annals of Surgery
Verified
Journal Article
Closed access
YSYun-Suhk Suh
Yun-Suhk Suh
DHDong-Seok Han
Dong-Seok Han
SKSeong-Ho Kong
Seong-Ho Kong
SKSebastianus Kwon
Sebastianus Kwon
CSCheong-Il Shin
Cheong-Il Shin
HYHan-Kwang Yang
Han-Kwang Yang
The purpose of this study is to compare the surgical, oncologic safety and the nutritional, functional benefit of laparoscopy-assisted pylorus-preserving gastrectomy (LAPPG) with laparoscopy-assisted distal gastrectomy (LADG) for middle-third early gastric cancers (EGC). Of those patients with middle-third EGC, it is still difficult to determine which procedure is better between LADG and LAPPG despite alleged advantages of LAPPG. For middle-third EGC, a retrospective analysis was performed comparing those who underwent LADG and those who underwent LAPPG. To evaluate surgical and oncologic safety, clinicopathologic differences including the postoperative morbidity, the pattern of lymph node metastasis and recurrence were analyzed. Postoperative protein, albumin, quantification of abdominal fat area using abdomen computed tomography, and the incidence of postoperative gallstone were compared for the evaluation of functional advantages. The overall postoperative morbidity rate was similar between LADG (n = 176) and LAPPG (n = 116). Delayed gastric emptying was less frequent in LADG than in LAPPG (1.7% vs 7.8%); however, the rates of all the other complications were significantly higher in LADG than in LAPPG (17.0% vs 7.8%). The number of examined lymph nodes and metastatic lymph nodes at each lymph node station was not significantly different and 3-year recurrence-free survival rates were also similar between LADG and LAPPG (98.8% vs 98.2%). Decreases in serum protein and albumin in postoperative 1 to 6 months and abdominal fat area in postoperative 1 year were significantly greater in LADG than in LAPPG. The 3-year cumulative incidence of gallstone was significantly higher in LADG than in LAPPG (6.5% vs 0.0%). For middle-third EGC, LAPPG can be considered as a better treatment option than LADG in terms of nutritional advantage and lower incidence of gallstone.

12 December 2014 in Hepatology
Verified
Journal Article
Open access
PDF file
BSBeomseok Suh
Beomseok Suh
SPSehhoon Park
Sehhoon Park
DSDongwook Shin
Dongwook Shin
JYJae Moon Yun
Jae Moon Yun
HYHyung‐Kook Yang
Hyung‐Kook Yang
BCBeLong Cho
BeLong Cho
Screening for hepatocellular carcinoma (HCC) is clinically important given that its early detection has remarkable survival benefits. We investigated the possible role of FIB‐4, a recently developed noninvasive marker for liver fibrosis based on routine laboratory tests, as a clinical indicator for predicting future HCC among hepatitis B surface antigen (HBsAg) carriers. Our retrospective cohort study involved 986 Korean HBsAg carriers 40 years of age or older who visited Seoul National University Hospital for a health checkup. National medical service claims data were used to determine HCC incidence. Median follow‐up time was 5.4 years (interquartile range: 4.4 years). Adjusted for age, sex, body mass index, smoking, alcohol, and antiviral medication for hepatitis B, compared to subjects with FIB‐4 <1.25, subjects with 1.7≤ FIB‐4 <2.4 showed an adjusted hazard ratio (aHR) of 4.57 (95% confidence interval [CI]: 1.50‐13.92) and subjects with FIB‐4 ≥2.4 showed an aHR of 21.34 (95% CI: 7.73‐58.92) for HCC incidence. FIB‐4 was shown to have incremental predictive value to ultrasonographic liver cirrhosis for HCC incidence (C‐index: 0.701 vs. 0.831; P = 0.001). FIB‐4 was also better predictive of HCC incidence, compared to that of ultrasonographic liver cirrhosis (C‐index: 0.775 vs. 0.701; P = 0.040). Conclusion: High FIB‐4 is a highly predictive risk factor for HCC incidence among Korean HBsAg carriers. FIB‐4 is a promising, easily applicable, and cost‐effective clinical tool in identifying a subpopulation of HBsAg carriers who are at heightened risk. Our study needs to be replicated in larger future studies on various ethnic groups; nonetheless, our study suggests that FIB‐4 may play a valuable role in HCC screening among HBsAg carriers. (Hepatology 2015;61:1261–1268)

14 February 2014 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
PDF file
IJIjin Joo
Ijin Joo
SLSang Min Lee
Sang Min Lee
JKJung Hoon Kim
Jung Hoon Kim
CSCheong‐Il Shin
Cheong‐Il Shin
JHJoon Koo Han
Joon Koo Han
BCByung Ihn Choi
Byung Ihn Choi

15 September 2015 in European Radiology
Verified
Journal Article
Closed access
PDF file
RKRihyeon Kim
Rihyeon Kim
SLSang Min Lee
Sang Min Lee
CSCheong-Il Shin
Cheong-Il Shin
ELEun Sun Lee
Eun Sun Lee
JYJeong Hee Yoon
Jeong Hee Yoon
BCByung Ihn Choi
Byung Ihn Choi

1 February 2014 in European Journal of Radiology
Verified
Journal Article
Closed access
YCYe Ra Choi
Ye Ra Choi
SKSe Hyung Kim
Se Hyung Kim
SKSun-Ah Kim
Sun-Ah Kim
CSCheong-Il Shin
Cheong-Il Shin
HKHyung Jin Kim
Hyung Jin Kim
BCByung Ihn Choi
Byung Ihn Choi

1 November 2017 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
HKHyuk Jung Kim
Hyuk Jung Kim
BJByeong Geon Jeon
Byeong Geon Jeon
CHChong Kun Hong
Chong Kun Hong
KKKye Won Kwon
Kye Won Kwon
SHSeung Bong Han
Seung Bong Han
KKKwang Pyo Kim
Kwang Pyo Kim